ImmunOs Therapeutics strengthens its Board of Directors along with raising CHF15m Series A financing co-led by BioMedPartners and Pfizer Ventures

– SWITZERLAND, Schlieren –  ImmunOs Therapeutics AG, a Swiss biotechnology company and leading developer of a next-generation innate immunity focused immunotherapy platform for cancer, today announced the closing of a CHF 15 million Series A financing round co-led by BioMedPartners and Pfizer Ventures with the participation of Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors.…